Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yep. So by the fact that he is chairman, his purchase now means that there is no imminent BO. Whether he is ultimately planning to take it private or a BO, what this means though is that he is interested in increasing shareholder value. So, whether BO or not, I am happy with a rising stock price.
No cap on PBM profits. The ACA capped profits at 20% for health insurance companies. In order to circumvent that insurers bought up all the PBMs, who had been in existence since the 1960s.
Is that I clearly would agree with the magistrate judge that the case should have gone forward and NOT dismissed. As JRoon states, it is not a given how any court would interpret all the details of the case, but to me it is clear that the original action should have gone to trial and not dismissed.
Amongst all the details, one thing that I found to be fairly egregious, was Hikma indicating that their drug was AB rated (therapeutically equivalent) to Vascepa for hypertriglyceridemia. That of course is totally false and it is only AB rated for Severe Hypertriglyceridemia.
This is a good read explaining the thought process of the original magistrate judge, the district court, and the appeals court. A good refresher for me for sure, which I will reread when I return home later today.
The IRS says that a wash sale exists if your spouse or a corporation you control purchases substantially identical stock within the wash sale rule 61-day period.
First Sleven, thanks for the link to the label. Secondly, I have not had a chance to closely scrutinize the label but would you say that number 5 could be a problem. For atrial fib and bleeding they are citing the R-I study.
Yep, selling specific share lots of AMRN (those with high cost basis in order to provide large losses) can definitely be used to offset gains in other stocks. If you have some shares with a very high cost basis, it does not take selling very many of them to offset good gains. Here in the U.S. one has to be careful that when we sell a stock to book a loss, that we do not repurchase that stock during a period starting 30 days before the sale to 30 days after. Or else that causes a wash sale.
There is no question that it seems that the Healthnet settlement accomplished very little. Heck maybe it was Amarin that wanted the settlement details sealed.
This was supposed to reduce injuries (the new kickoff format) but it seems to me that there still are plenty of injuries happening this year. Some teams getting decimated with injuries. Although I will say that when I played high school football (must have been a hundred years ago it seems) and I was on the kickoff squad, I did see one of our guys have a really gruesome injury on one kickoff. Kind of turned my stomach a bit. Broke his leg and bone clearly sticking out.
That could be just their manner of parlance. A way for them to indicate that it is added to the subjects' daily diet.
The Icosapent-ethyl (IPE) will be purchased from BASF S.A., Avenida Nacoes Unidas, 14171, 04794-000 Sao Paulo, Brazil, and the oil will be encapsulated in a Brazilian company still not defined.
making, selling, offering to sell, and importing into the United States any drug product for a use that is covered by the ’537, ’077, and ’861 patents
So could they get around it and continue selling GV by saying that it is not intended for a use covered by the aforementioned patents? Only intended for Marine, but we all know what will happen after that and they can say it is not them filling the script.
No doubt. The question is, if by chance Amarin was to prevail in early 2027 would the other Generics pull back or feel that their circumstances are different and they couldn't convicted of infringing and continue selling GV? We know it is more than just the Generic companies that are causing the infringement. PBMs, insurance cos, pharmacies, docs all in cahoots.
JRPac, thanks for doing whatever you did so we could see more detail. So almost a year before the deadline for discovery, assuming (I know what they say about ass u me) there are no delays. Some people point to discovery as being possibly the tipping point to possibly spurring the parties to the negotiating table. If not the trial then about 10 months after that. I don't understand how any settlement helps much unless it involves all the other Generic companies, but if anyone has ideas about that...
Was going to reply to Seve to say that while I know close to ZERO when it comes to negotiating with EU countries for drug reimbursement, it seems to me that wrt all those countries mentioned, the applications were put in before Denner gained control. Of course, I don't know about the process after that and what the company additionally submitted and also whether they were confined by the initial application. I was thinking along the lines of finding out if and whether Denner-led Amarin could have argued for that "Netflix" type of arrangement that he mentioned during the conflict with prior management phase. As I was searching for info online about that I came across an old story but it tickled my brain into a couple of thoughts. Here is the link to the old story: https://www.biospace.com/amarin-shares-plunge-following-ruling-in-vascepa-patent-lawsuit, but let me mention the two thoughts that it triggered.
Firstly, the story mentions the stock dropping 70% in premarket the morning after the Du decision - yeah we know it went to $4. Thinking about it today, that signals that the whole investing world realized that even though the ONLY patents that were invalidated (and the ONLY indication the generics could market to) were for the Marine indication, that Amarin's major indication (CVD) would be decimated. Common knowledge, yet no one could stop it. Does anyone think that in these last 4 1/2 years if the only scripts that were filled were for VH trigs (over 500) that our stock price wouldn't be significantly higher than $4?
Secondly, some of the things Thero is quoted as saying right after the ruling ring hollow:
In a statement issued following the ruling, Amarin said it “strongly disagrees” with the ruling and will “vigorously pursue all available remedies,” which could include an appeal of the court’s decision. Amarin Chief Executive Officer John Thero said Amarin could also seek preliminary injunction pending that appeal against any generics that could be approved by the FDA and launched prior to the day in court. Thero went on to note that the company will take all legal actions necessary to “defend and protect” the company’s intellectual property...................We believe we are favorably situated to obtain an injunction against generic launch pending appeal, subject to our posting a bond to secure generics’ lost profits in the event that generics prevail on appeal,” Thero said in a statement.
I think most of us would agree that Amarin did NOT “vigorously pursue all available remedies,” as majorly evidenced by them not supporting Marjac/North's efforts. Also, I can't remember so maybe someone can refresh my memory but did they seek injunctions as Thero outlined?
I know all this is about stuff like water under the bridge, but it struck me that immediately after the decision the entire world basically knew that the Generics would steal the CV indication for V. A corrupt system.
I keep thinking that when I watch an NFL game sometimes when a referee screws up a call against one team on the next play it is as if he tries to even it up and call one on the other team. I am always hoping that the pendulum finally swings the other way and we start benefitting from the infringement case against Hikma. I realize that will unfortunately take some time.
Chart looks a reversal today - possibly closing lower than the open - but the volume is anemic so it might not mean anything. Hopefully, it regains strength before the close.
Those tech stocks of yours have been roaring this week. Like I may have mentioned I did make a little coin twice in PLTR and would re-enter on a pull back but they all seem at sky high valuations right now. Of course we know the market can stay irrational longer than I can stay solvent. Longer term not all those companies in those industries will thrive but for the time being investors are betting on all of them. Of course you have got plenty of profit in them and I know you wisely use money management and cull profits when appropriate. Today I have been shopping buying oil stocks where there is blood in the streets. Eventually they will revert and in the meantime I can collect divs. Thanks for news on ARDX and UNCY.
Scroll down that page and look at so many of those patents that have become utterly useless. I hope they get their patent application fees returned to them.
Dar, appreciate being called steadfast and lumped in with those heavyweights. We are all in this together. And, you are right about the fear of jumping positions. It would be real easy to dump and Amarin and you could easily find a very, very safe dividend stock, but you will never make back your money that way. To find something that has the chance to give you a 10x return, to make up lost money here, would mean getting into something that by definition would be risky and could backfire stupendously. We know what we have here.
Yep, my take as well. That is why I questioned those rejected scripts since they sounded like they would have absorbed cost. This is out there so I would hope that it is priced in but you know when news story comes out there is a knee jerk reaction. Or sometimes after the stock moves one way or another then they write the story offering up reasons
So it appear that although it is oil based, it is not the oil that is the active ingredient that does the magic. It is an anesthetic called ropivacaine.
I have been scolded in the past for bringing that up too many times, but there is no question that that was the most impactful moment for Amarin's business going forward. It could have been so much different otherwise. We, I guess, will never know if a settlement could have been reached (and I am not even considering all the trial mistakes made by Amarin's legal team). Don't know if the defendants would never have accepted any kind of settlement and were dead set on throwing the dice by going to trial, or whether their demands seemed to high for management. If the latter, it is clear with what has happened to the business since, that no matter how high a monetary settlement they were seeking, it would have been worth it for us.
Kiwi, I understand the reasoning as to why ARDX would have the most immediate benefit if the KA passes. But I would assume by the same logic that if the KA fails to be passed that UNCY would drop less than ARDX?
Kiwi, I have a question for you. I listened to most of the fireside chat today with Piper Sandler. Overall I thought they were hopeful but slightly resigned to the chance that the KPA does not pass before the end of the year. And discussing the "what if it doesn't pass", they kept emphasizing that they wanted to make sure the patient had access no matter what. I think they called it "patient assist" or something like that. They indicated that they would subside the cost for the patient if need be (the finance guy said it would go to SGA when questioned about how it would affect Q1 revenue).
So my thoughts drifted to your commentary the other day relating the experience of your wife and those denied scripts. Did no one contact Ardelyx to have them assist with getting those scripts? That is what they are saying in all these conferences that they will make sure patients still get their meds. Side note, there was a mention that nephrologists are apoplectic concerning all these rules going into play on Jan. 1.
Yeah this is crazy. Between the scripts being denied and Ernie reminding me of the gooberment, I lightened up the other day. 43 sponsors. Heck my SS Fairness Act has 330 sponsors and still waiting for the Senate to act. SMH.
North, did you vote in relation to the RS for HSCS that happened in May? 1 for 100 and since the stock has slid another 50%. Notice CDIO is planning a RS in the near future or maybe that has happened already not sure, but that stock is way down too.
OT. United Healthcare CEO shot and killed in NYC this morning. There for an investor's conference. Police say they believe it was a targeted killing. Have to wait for facts, but wondering who would be so mad to do this.
News 
Market Data 
Discover 
AI
